Loading...
XASX
MAP
Market cap22mUSD
Dec 05, Last price  
0.08AUD
1D
0.00%
1Q
-16.67%
IPO
-80.00%
Name

Microba Life Sciences Ltd

Chart & Performance

D1W1MN
XASX:MAP chart
P/E
P/S
2.78
EPS
Div Yield, %
Shrs. gr., 5y
7.11%
Rev. gr., 5y
45.91%
Revenues
12m
+123.06%
1,828,1552,909,0263,732,4434,688,6455,420,13612,090,055
Net income
-20m
L+57.24%
-4,733,829-6,650,667-7,523,752-11,470,429-12,680,212-19,938,485
CFO
-16m
L+25.60%
-3,620,558-4,323,278-7,181,584-10,448,812-12,393,828-15,566,936

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
IPO date
Apr 05, 2022
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT